The evidence on modafinil
5-minute read
The evidence on modafinil
Modafinil is one of the most extensively studied wakefulness compounds in clinical pharmacology. Three decades of peer-reviewed research. Approved by every major drug regulator. Field-deployed by multiple militaries. The case is on the table; razumna ships the molecule.
“When more complex assessments are used, modafinil appears to consistently engender enhancement of attention, executive functions, and learning. We did not observe any preponderances for side effects or mood changes.”
Systematic review of modafinil for cognitive enhancement in healthy non-sleep-deprived adults, pooled 24 controlled trials, 1990–2014
Approved by every major drug regulator
Modafinil cleared the highest regulatory bars on five continents. Full prescribing information, indications, dosing, safety, is publicly documented.
What the research consistently shows
Three decades of clinical research, three reproducible findings.
Executive function gains hold across complex tasks
“Modafinil appears to consistently engender enhancement of attention, executive functions, and learning.”
Battleday & Brem (2015) · European Neuropsychopharmacology · PubMed 26381811
Mechanism is selective, not blunt stimulation
“Modafinil directly increases cortical catecholamine levels, indirectly upregulates cerebral serotonin, glutamate, orexin, and histamine levels.”
Battleday & Brem (2015) · mechanism summary · PubMed 26381811
Lower addictive potential than classical stimulants
“Modafinil has lower addictive potential than classical stimulants such as amphetamine, cocaine, or methylphenidate.”
Wikipedia/Modafinil citing Volkow et al. · CC-BY-SA
Field-deployed by multiple militaries
Modafinil is the wakefulness compound that multiple western militaries field-test and issue for sustained-operations missions. The pharmacology is suited to it: sustained alertness without amphetamine’s mood and cardiovascular cost.
From the Wikipedia Modafinil entry: “Military forces in several countries, including France, the United States, and the United Kingdom, have used modafinil as an alternative to amphetamines for managing fatigue during combat operations.”
U.S. Air Force protocol permits modafinil for missions exceeding six hours since 2003. France approved it for fighter pilots in 1986, before the FDA approved it for narcoleptics. The military adoption is the field validation: when a pilot or operator has to be reliably alert for twelve hours and a stimulant crash is unacceptable, this is the compound they pick.
Source: Wikipedia/Modafinil (CC-BY-SA, citing DoD and DGA records)
From the NIH’s consumer drug information
“Modafinil is used to treat excessive sleepiness caused by narcolepsy or shift work sleep disorder, and obstructive sleep apnea/hypopnea syndrome. It works by changing the amounts of certain natural substances in the area of the brain that controls sleep and wakefulness.”
Source: medlineplus.gov (public domain, U.S. Government)
Where the modafinil community actually talks
Vendor-independent discussion. Razumna runs no accounts in these venues and curates nothing. Read before ordering from any vendor in this category, razumna included.
Largest English-language cognitive-enhancement community on Reddit. Vendor self-promo is restricted; buyer-to-buyer experience reports.
Dedicated subreddit. Use protocols, side-effect management, dose timing. Less vendor-focused than the wider community.
Every peer-reviewed study indexed by the U.S. National Library of Medicine. Free to search, free to read abstracts.
Primary research, additional citations
Mignot et al., modafinil binding pharmacology
Originally published in Sleep. Established the binding profile that distinguishes modafinil from amphetamine-class wakefulness drugs.
PubMed 7973317 →Minzenberg & Carter, modafinil’s neurochemical actions and effects on cognition
Published in Neuropsychopharmacology. The comprehensive mechanism review, receptor systems, neurotransmitter modulation, cognitive endpoints.
PubMed 17914514 →Volkow et al., modafinil’s effect on dopamine transporters in the human brain
Published in JAMA. The PET-imaging study that mapped therapeutic-dose modafinil’s effect on dopamine transporters in living human subjects.
PubMed 19293415 →Battleday & Brem, modafinil for cognitive enhancement in healthy non-sleep-deprived subjects
Published in European Neuropsychopharmacology. Pooled 24 controlled trials. The headline finding razumna leads with on every page.
PubMed 26381811 →Roth et al., modafinil long-term wakefulness data in narcolepsy
The multi-year safety and efficacy data across narcoleptic patients, the safety record that underpins regulatory confidence.
PubMed 17561600 →Darwish et al., armodafinil vs modafinil PK profile
Direct comparison of armodafinil and modafinil pharmacokinetics in healthy subjects, the basis for the dose-equivalence calculations in razumna’s catalog.
PubMed 19725664 →Kumar, approved and investigational uses of modafinil, an evidence-based review
Published in Drugs. Comprehensive review of approved indications and investigational off-label applications.
PubMed 18840034 →Browse the complete PubMed index of modafinil research at pubmed.ncbi.nlm.nih.gov/?term=modafinil.